The abnormal growth patterns continue throughout the growing years; therefore, intervention, accurate diagnosis, and a customized, expertly carried-out treatment plan should be a primary concern. Although the timing of surgery can be highly individualized, surgical correction of the bicoronal craniosynostosis is most often done between 6 and 12 months of age. Surgery is usually performed through a scalp incision that lies concealed within the hair of the head. Your craniofacial surgeon will work in concert with a pediatric neurosurgeon in order to safely remove the bones of the skull. Then, the craniofacial surgeon reshapes and repositions those bones to give a more normal skull shape. References
Rannan-Eliya SV, Taylor IB, De Heer IM, Van Den Ouweland AM, Wall SA, Wilkie AO (August 2004). "Paternal origin of FGFR3 mutations in Muenke-type craniosynostosis". Hum. Genet. 115 (3): 200–7. doi:10.1007/s00439-004-1151-5. PMID 15241680. S2CID 24791706. Agochukwu NB, Doherty ES, Muenke M (December 7, 2010). "Muenke Syndrome". Gene Reviews. PMID 20301588. Hughes J, Nevin NC, Morrison PJ (2001). "Familial craniosynostosis due to Pro250Arg mutation in the fibroblast growth factor receptor 3 gene". Ulster Med J. 70 (70): 47–50. PMC 2449219. PMID 11428324. Morris-Kay GM, Wilkie AO (2005). "Growth of the normal skull vault and its alteration in craniosynostosis: Insights from human genetics and experimental studies". Journal of Anatomy. 207 (5): 637–653. doi:10.1111/j.1469-7580.2005.00475.x. PMC 1571561. PMID 16313397. Solomon BD, Muenke M (2010). "Craniosynostosis: Molecular Genetics". Principles of Diagnosis and Treatment. 19: 89–97. External links
National Institute of Healths Reference
GeneReview/NIH/UW entry on Muenke Syndrome
Midol is a brand of over-the-counter analgesic drugs marketed for menstrual cramping and other effects related to premenstrual syndrome and menstruation. Various subbrands are formulated using different active ingredients. Midol is distributed by Bayer. Midol was originally sold in 1911 as a headache and toothache remedy that was considered safer because it did not use the narcotics typically used at the time. It was then promoted as a cure for hiccups claiming it controlled spasms, and finally as a remedy for menstrual cramps and bloating. A formulation sold in the 1980s was made with the sympathomimetic cinnamedrine. It had been reported to have abuse potential as an appetite suppressant and sympathomimetic agent. The "Midol Complete" formulation consists of:

Acetaminophen 500 mg (pain reliever)
Caffeine 60 mg  (stimulant)
Pyrilamine maleate 15 mg (antihistamine)The "Extended Relief" formulation consists of:

Naproxen sodium 220 mg (NSAID, pain reliever/fever reducer)The "Teen" formulation consists of:

Acetaminophen 500 mg (pain reliever)
Pamabrom 25 mg (diuretic)The "Liquid Gels" formulation consists of:

Ibuprofen 200 mg (NSAID, pain reliever)The "PM" formulation consists of:

Acetaminophen 500 mg (pain reliever)
Diphenhydramine citrate 38 mg (sedative antihistamine)There are concerns drugs like Midol, which is an NSAID, increases risk of bleeding, kidney damage and has other negative effects on cardiovascular system. References
External links
Official website